- Home
- PSBD vs CYRX Comparison
PSBD vs CYRX Comparison
Compare PSBD & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- CYRX
- Stock Information
- Founded
- PSBD 2009
- CYRX 1999
- Country
- PSBD United States
- CYRX United States
- Employees
- PSBD N/A
- CYRX N/A
- Industry
- PSBD
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- CYRX Health Care
- Exchange
- PSBD Nasdaq
- CYRX Nasdaq
- Market Cap
- PSBD 454.5M
- CYRX 438.7M
- IPO Year
- PSBD 2024
- CYRX N/A
- Fundamental
- Price
- PSBD $14.19
- CYRX $8.86
- Analyst Decision
- PSBD Buy
- CYRX Strong Buy
- Analyst Count
- PSBD 4
- CYRX 10
- Target Price
- PSBD $14.38
- CYRX $11.70
- AVG Volume (30 Days)
- PSBD 84.9K
- CYRX 1.1M
- Earning Date
- PSBD 08-06-2025
- CYRX 08-05-2025
- Dividend Yield
- PSBD 12.47%
- CYRX N/A
- EPS Growth
- PSBD N/A
- CYRX N/A
- EPS
- PSBD N/A
- CYRX 1.35
- Revenue
- PSBD N/A
- CYRX $237,879,000.00
- Revenue This Year
- PSBD N/A
- CYRX N/A
- Revenue Next Year
- PSBD N/A
- CYRX $9.08
- P/E Ratio
- PSBD N/A
- CYRX $6.49
- Revenue Growth
- PSBD N/A
- CYRX 24.93
- 52 Week Low
- PSBD $11.51
- CYRX $4.58
- 52 Week High
- PSBD $16.82
- CYRX $9.48
- Technical
- Relative Strength Index (RSI)
- PSBD 56.09
- CYRX 58.38
- Support Level
- PSBD $13.80
- CYRX $8.57
- Resistance Level
- PSBD $14.43
- CYRX $8.99
- Average True Range (ATR)
- PSBD 0.32
- CYRX 0.47
- MACD
- PSBD 0.02
- CYRX -0.02
- Stochastic Oscillator
- PSBD 64.71
- CYRX 71.34
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.